LUMIBIRD overview

Lannion, November 27, 2024 – 8:00 am LUMIBIRD: EXPLORATORY PROJECT TO SELL THE MEDICAL DIVISION Following market rumours, Lumibird (FR0000038242 - LBIRD) confirms that it is currently exploring the potential sale of its medical division. Lumibird is at a very early stage of the process and there can be no certainty as to its outcome. The Company will communicate in due course in accordance with applicable regulations. LUMIBIRD is one of the world's leading laser specialists. With 50 years'...

Lannion, October 15, 2024 – 17:45 pm LUMIBIRD: BANKS RENEW THEIR CONFIDENCE IN THE GROUP'S STRATEGY WITH FINANCING OF OVER €100M 55.2m repayable over 7 years, to reschedule existing loans 50m to be drawn over 3 years to finance acquisitions The LUMIBIRD Group (FR0000038242 - LBIRD), the European leader in laser technologies, announces that it has finalised bank financing of more than €100m to reschedule its current borrowings, particularly in view of the maturity of its bond debt, and to...

Lannion, July 24, 2024 – 17:35 LUMIBIRD RECEIVES NEW ORDERS FROM THALES The LUMIBIRD Group (FR0000038242 - LBIRD), a European leader in laser technologies, announces that Lumibird Photonics Sweden AB has recently received major orders from Thales for laser rangefinders. The total order value is approximately SEK 150 million (€12.8m), adding to the contracts previously announced, and the contract period is 2025-2028. The work will be carried out at the Lumibird facility in Gothenburg, Sweden....

Lannion, May 22, 2024 – 5:45 pm LUMIBIRD PRESENTS ITS NEW STRATEGIC PLAN The LUMIBIRD Group (FR0000038242 - LBIRD), the European leader in laser technologies, presents its new strategic plan at its Capital Market Day. The Group confirms its objectives of an organic compound annual growth rate (CAGR) of over 8% by 2026, and an EBITDA margin at least 500 basis points higher than in 2023. The company's growth objective is underpinned by its key positioning in buoyant markets, particularly in...

Lannion, 3 May 2024 – 7:30 am LUMIBIRD MEDICAL OBTAINS CE MARKING FOR C.DIAG ® , A PLATFORM TO HELP DIAGNOSE DRY EYE The LUMIBIRD Group (FR0000038242 - LBIRD), the European leader in laser technologies, announces the launch by Lumibird Medical of C.DIAG ® , a new-generation dry eye diagnostic aid platform incorporating Artificial Intelligence. This Europe-wide launch follows the CE marking certified by LNE-GMED on 30 April 2024. This new product completes the C.SUITE TM offering with...

Lannion, January 26, 2024 FINANCIAL COMMUNICATIONS AGENDA LUMIBIRD [FR0000038242 – LBIRD], the European leader for laser technologies, publishes its financial communications agenda for 2024. Disclosure date Closed period FY 2023 revenues Monday 29/01/2024 FY 2023 earnings Tuesday 12/03/2024 from 12/02/2024 to 12/03/2024 included Q1 2024 revenues Monday 22/04/2024 Annual Shareholders Meeting Tuesday 29/04/2024 H1 2024 revenues Monday 22/07/2024 H1 2024 earnings Tuesday 24/09/2024 from...